Antabuse
Disulfiram
Sourced from the FDA Orange Book
Key dates
Key dates
No patent or exclusivity dates are listed for this product.
Pharmaceutical detail
Pharmaceutical detail
Active ingredient
DISULFIRAM
Strength
500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
NDA 007883
Product number
002
Marketing status
Discontinued
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Other strengths in NDA 007883
Active-ingredient family
This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2015DisulfiramGeneric (ANDA)
ANDA 203916 · Natco Pharma USA
- 2014DisulfiramGeneric (ANDA)
ANDA 202652 · Hikma
- 2013DisulfiramGeneric (ANDA)
ANDA 091681 · Alvogen
- 2012DisulfiramGeneric (ANDA)
ANDA 091563 · Chartwell Molecules
- 2011DisulfiramGeneric (ANDA)
ANDA 091619 · Sigmapharm Labs LLC
- 1984DisulfiramGeneric (ANDA)
ANDA 088792 · Strides Pharma Intl
- 1984DisulfiramGeneric (ANDA)
ANDA 088793 · Strides Pharma Intl
- 1983AntabuseGeneric (ANDA)
ANDA 088482 · Odyssey Pharms
- 1983AntabuseGeneric (ANDA)
ANDA 088483 · Odyssey Pharms
- 1983DisulfiramGeneric (ANDA)
ANDA 087973 · Watson Labs
- 1983DisulfiramGeneric (ANDA)
ANDA 087974 · Watson Labs
- —DisulfiramGeneric (ANDA)
ANDA 086889 · Watson Labs
Listed patents
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Antabuse — frequently asked questions
Approval, therapeutic equivalence, patents, and exclusivity for this product, from the FDA Orange Book.
Built directly from the FDA Orange Book data file. This product page links back to the Disulfiram active-ingredient family, which is the canonical reference for generics, patents, and exclusivity across all strengths.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.

